The company's customer wins this year suggest more revenue expansion to come. In fact, C3.ai forecasts fiscal 2026 sales to ...

This has led to strong growth for the company, with C3.ai's revenue rising 25% year over year in fourth-quarter fiscal year 2025 (ending April 30). It also expects strong growth for FY 2026, with ...

Upgrade your portfolio! C3.ai is a strong buy with explosive growth, top-tier partnerships, and AI exposure at a discount.

Apellis Pharmaceuticals Inc. (NASDAQ:APLS) is one of the biotech stocks to buy according to Wall Street analysts.

Segment operating income2 in the second quarter of 2025 was $172 million and segment operating margin2 was 5.6%, compared to $203 million and 6.8%, respectively, in the second quarter of 2024. The ...

Founded in 2009 by Thomas Siebel, C3.ai's core purpose has always been to deliver AI solutions to enterprises. Its value ...

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of C3.ai's market ...

The stocks bucked a mostly optimistic broader market, with the tech-heavy Nasdaq and the S&P 500 both up by 0.18 percent and ...

C3.ai announced today that CEO Tom Siebel would be stepping down and that the company was in the process of looking for its ...

C3 AI founder and Chief Executive Officer Tom Siebel today announced that he will step down because of health issues.

Shares of artificial intelligence (AI) software company C3.ai (NYSE:AI) fell 10% in the afternoon session after the company ...

("C3 AI," "C3," or the "Company") (NYSE: AI), the Enterprise AI application software company, today announced that it has initiated a search for Mr. Siebel's successor as Chief Executive Officer of C3 ...